UPDATE 2-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court
January 07, 2019 at 10:25 AM EST
The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a $200 million verdict against rival drugmaker Gilead Sciences Inc in a dispute involving blockbuster hepatitis C drugs.